Brief: CVRx Q2 Revenue USD 13.589 Million Vs. IBES Estimate USD 13.2 Million

CVRx

04/08/2025 21:05

Overview

CVRx Q2 revenue grows 15% yr/yr, beating analyst expectations, per LSEG data

Net loss for Q2 was $14.7 mln, despite revenue growth

CMS proposed favorable reimbursement changes for Barostim implant procedures

Outlook

CVRx expects 2025 revenue between $13.7 mln and $14.7 mln for Q3

CVRx narrows full-year 2025 revenue outlook between $55 mln and $57 mln

Company expects 2025 gross margin of 83% to 84%

CVRx anticipates 2025 operating expenses of $96 mln to $98 mln

Result Drivers

US HF GROWTH - Revenue increase driven by expansion into new sales territories and accounts, and increased awareness of Barostim

IMPLANTING CENTERS - Active implanting centers in the U.S. grew to 240, boosting revenue

CMS PROPOSAL - Favorable reimbursement changes proposed by CMS for Barostim implant procedure

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$13.59 mln
$13.20 mln (7 Analysts)
Q2 EPS
-$0.57
Q2 Net Income
-$14.74 mln
Q2 Gross Margin
84.0%
Q2 Basic EPS
-$0.57
Q2 Gross Profit
$11.45 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for CVRx Inc is $12.00, about 37% above its August 1 closing price of $7.56

Press Release: ID:nGNX4BFnPb

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)